Nanjing Medlander Medical Technology Co.,Ltd. (SHA:688273)
China · Delayed Price · Currency is CNY 46.70
+0.55 (1.19%)
Apr 29, 2026, 4:00 PM EDT
SHA:688273 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 400.74 | 419.82 | 418.41 | 320.87 | 353.18 | 338.7 |
Other Revenue | 11.77 | 11.77 | 6.14 | 19.96 | 23.71 | 2.94 |
| 412.52 | 431.59 | 424.55 | 340.82 | 376.89 | 341.64 | |
Revenue Growth (YoY) | -5.92% | 1.66% | 24.57% | -9.57% | 10.32% | 1.52% |
Cost of Revenue | 129.29 | 130.95 | 119.06 | 98.92 | 118.88 | 92.66 |
Gross Profit | 283.23 | 300.64 | 305.49 | 241.9 | 258.01 | 248.98 |
Selling, General & Admin | 163.52 | 163.29 | 149.36 | 127.84 | 116.86 | 102.16 |
Research & Development | 59.3 | 61.27 | 57.33 | 58.24 | 41.34 | 37.23 |
Other Operating Expenses | -6.57 | -7.56 | -6.96 | -10.75 | -7.59 | -4.57 |
Operating Expenses | 217.93 | 218.25 | 200.54 | 175.78 | 153.44 | 135.38 |
Operating Income | 65.3 | 82.39 | 104.94 | 66.12 | 104.57 | 113.6 |
Interest Expense | -1.41 | -1.39 | -1.06 | -0.38 | -0.3 | -0.15 |
Interest & Investment Income | 9.48 | 11.07 | 13.26 | 28.76 | 17.28 | 5.55 |
Currency Exchange Gain (Loss) | -0.08 | -0.08 | 0.03 | -0.03 | - | - |
Other Non Operating Income (Expenses) | -0.68 | -0.57 | -0.57 | -0.27 | -0.09 | -0.03 |
EBT Excluding Unusual Items | 72.61 | 91.42 | 116.59 | 94.19 | 121.45 | 118.97 |
Impairment of Goodwill | -0.67 | -0.67 | -9.61 | - | - | - |
Gain (Loss) on Sale of Investments | -0.46 | - | 1.02 | 0.65 | - | - |
Gain (Loss) on Sale of Assets | -0.18 | -0.12 | -0.26 | 0.23 | -0 | 0.31 |
Asset Writedown | - | - | -0.18 | - | - | - |
Other Unusual Items | 15.71 | 15.72 | 17.57 | 6.4 | 24.44 | 10.46 |
Pretax Income | 87.01 | 106.35 | 125.13 | 101.48 | 145.9 | 129.73 |
Income Tax Expense | 3.92 | 6.52 | 16.23 | 9 | 16.61 | 10.04 |
Earnings From Continuing Operations | 83.1 | 99.83 | 108.9 | 92.48 | 129.29 | 119.7 |
Minority Interest in Earnings | 2.6 | 2.8 | -7.32 | -2.67 | -7.6 | -1.31 |
Net Income | 85.7 | 102.63 | 101.58 | 89.82 | 121.68 | 118.38 |
Net Income to Common | 85.7 | 102.63 | 101.58 | 89.82 | 121.68 | 118.38 |
Net Income Growth | -18.51% | 1.03% | 13.10% | -26.19% | 2.79% | -2.91% |
Shares Outstanding (Basic) | 98 | 98 | 99 | 100 | 83 | 75 |
Shares Outstanding (Diluted) | 98 | 98 | 99 | 100 | 83 | 75 |
Shares Change (YoY) | -0.42% | -0.73% | -1.46% | 20.00% | 11.11% | 0.00% |
EPS (Basic) | 0.88 | 1.05 | 1.03 | 0.90 | 1.46 | 1.58 |
EPS (Diluted) | 0.88 | 1.05 | 1.03 | 0.90 | 1.46 | 1.58 |
EPS Growth | -18.16% | 1.77% | 14.77% | -38.49% | -7.49% | -2.92% |
Free Cash Flow | 8.86 | -12.73 | -7.2 | 61.76 | 72.41 | 134.01 |
Free Cash Flow Per Share | 0.09 | -0.13 | -0.07 | 0.62 | 0.87 | 1.79 |
Dividend Per Share | 0.800 | 0.800 | 0.800 | 0.600 | 1.300 | - |
Dividend Growth | - | - | 33.33% | -53.85% | - | - |
Gross Margin | 68.66% | 69.66% | 71.95% | 70.97% | 68.46% | 72.88% |
Operating Margin | 15.83% | 19.09% | 24.72% | 19.40% | 27.74% | 33.25% |
Profit Margin | 20.77% | 23.78% | 23.93% | 26.35% | 32.29% | 34.65% |
Free Cash Flow Margin | 2.15% | -2.95% | -1.70% | 18.12% | 19.21% | 39.23% |
EBITDA | 86.98 | 103.77 | 125.08 | 79.37 | 115.3 | 122.62 |
EBITDA Margin | 21.09% | 24.04% | 29.46% | 23.29% | 30.59% | 35.89% |
D&A For EBITDA | 21.68 | 21.38 | 20.14 | 13.25 | 10.73 | 9.02 |
EBIT | 65.3 | 82.39 | 104.94 | 66.12 | 104.57 | 113.6 |
EBIT Margin | 15.83% | 19.09% | 24.72% | 19.40% | 27.74% | 33.25% |
Effective Tax Rate | 4.50% | 6.13% | 12.97% | 8.87% | 11.38% | 7.74% |
Revenue as Reported | 412.52 | 431.59 | 424.55 | 340.82 | 376.89 | 341.64 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.